COVID-19 and Pulmonary Hypertension: An Interesting Dynamic.

Publication date: Feb 24, 2024

The dynamic between pulmonary hypertension (PH) and COVID-19 has been under investigation since 2020, early in the pandemic. Although the pathophysiology of PH has been well-studied, new discoveries regarding the multisystemic effects of COVID-19 are still being uncovered. The cardiopulmonary effects of COVID-19 have led investigators to inquire about the interplay between these 2 conditions. Several factors are suggested to contribute to an increased risk of developing PH after infection with SARS-CoV-2. This includes cytokine storm, acute respiratory distress syndrome, and fibrotic changes seen in post-COVID-19 lung disease. Additionally, it has been proposed that certain medications used to treat PH may be applied to patients suffering from the cardiopulmonary complications of COVID-19. This review will focus on the interplay between COVID-19 and PH, with a special focus on the risk of developing PH after SARS-CoV-2 infection and the outcomes of patients with preexisting PH who are diagnosed with COVID-19. The potential benefits of utilizing off-label PH medications for COVID-19 patients will also be discussed.

Concepts Keywords
Cardiol Cardiopulmonary
Hypertension Cov
Investigators Covid
Storm Developing


Type Source Name
disease MESH COVID-19
disease MESH Pulmonary Hypertension
disease MESH infection
disease MESH cytokine storm
disease MESH acute respiratory distress syndrome
disease MESH lung disease
disease MESH complications
pathway REACTOME SARS-CoV-2 Infection
disease MESH Long Covid

Original Article

(Visited 1 times, 1 visits today)